(Q38006132)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Passive immunity in the prevention of rabies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Craig J van Dolleweerd

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Daniel L. Horton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Julian Ma

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

6

Anthony R Fooks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Leonard Both

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

397-407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

Discovery and development of biopharmaceuticals: current issues

30 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Historic aspects of intravenous immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Passive antibody therapy for infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The growth and potential of human antiviral monoclonal antibody therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Monoclonal antibody-based therapies for microbial diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Clinical practice. Prophylaxis against rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The clinical picture of rabies in man

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Pathophysiologic studies in human rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Ikoma lyssavirus, highly divergent novel lyssavirus in an African civet

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Possible emergence of West Caucasian bat virus in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Shimoni bat virus, a new representative of the Lyssavirus genus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Fatal human infection with rabies-related Duvenhage virus, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Fatal human rabies due to Duvenhage virus from a bat in Kenya: failure of treatment with coma-induction, ketamine, and antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies epidemiology and control in Turkey: past and present

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Evolution of European bat lyssaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Repeated detection of European bat lyssavirus type 2 in dead bats found at a single roost site in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

European bat lyssaviruses: an emerging zoonosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Human rabies due to lyssavirus infection of bat origin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Australian bat lyssavirus infection: a second human case, with a long incubation period

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Use of hyperimmune anti-rabies serum concentrates in experimental rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies prophylaxis in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The cell biology of rabies virus: using stealth to reach the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies encephalitis in malaria-endemic area, Malawi, Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The challenge to provide affordable rabies post-exposure treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

1 reference

7 January 2021

Management of rabies in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Viewpoint: Management of human rabies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Unexplained rabies in three immigrants in the United States. A virologic investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Diffusion and fate of intramuscularly injected human rabies immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Failure of postexposure treatment of rabies in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-1998. A 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Clinical use of human globulin immune to rabies virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Acute rabies death mediated by antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

"Early death" and the contraindication of vaccine during treatment of rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line (P388D1).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Drug and gene targeting to the brain with molecular Trojan horses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Survival after treatment of rabies with induction of coma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies, still neglected after 125 years of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies and African bat lyssavirus encephalitis and its prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies - the need for a 'one medicine' approach

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies in China: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Epidemiological investigations of human rabies in China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Overview of rabies in the Americas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Epidemiology of rabies post-exposure prophylaxis--United States of America, 2006-2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Five-year (January 2004-December 2008) surveillance on animal bite and rabies vaccine utilization in the Infectious Disease Hospital, Dhaka, Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Emerging viruses: coming in on a wrinkled wing and a prayer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies transmitted by vampire bats to humans: an emerging zoonotic disease in Latin America?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Postexposure rabies vaccination in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Mass human exposure to rabies in New Hampshire: exposures, treatment, and cost

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

An outbreak of bat-transmitted human rabies in a village in the Brazilian Amazon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Novel vaccines to human rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The incurable wound revisited: progress in human rabies prevention?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The fight against rabies in Africa: From recognition to action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies situation in Cambodia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

New lyssavirus genotype from the Lesser Mouse-eared Bat (Myotis blythi), Kyrghyzstan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Bat lyssaviruses (Aravan and Khujand) from Central Asia: phylogenetic relationships according to N, P and G gene sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Novel lyssaviruses isolated from bats in Russia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Efficacy of rabies biologics against new lyssaviruses from Eurasia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Quantifying antigenic relationships among the lyssaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Studies on the different conditions for rabies virus neutralization by monoclonal antibodies #1-46-12 and #7-1-9.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Mechanisms of rabies virus neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Chromatographic purification of equine immunoglobulin G F(ab)2 from plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Research and development of next generation of antibody-based therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Therapeutic antibodies for autoimmunity and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Development trends for human monoclonal antibody therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The safety and side effects of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Function and glycosylation of plant-derived antiviral monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

A Rabies-Specific Human Monoclonal Antibody That Protects Mice Against Lethal Rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

An antibody produced in tobacco expressing a hybrid beta-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Strategies and challenges for the next generation of therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Antibody processing and engineering in plants, and new strategies for vaccine production.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Canine vaccination--providing broader benefits for disease control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Molecular epidemiology of rabies in Southern People's Republic of China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Human rabies in China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Pivotal role of dogs in rabies transmission, China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Renewed global partnerships and redesigned roadmaps for rabies prevention and control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Risk factors associated with travel to rabies endemic countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Rabies awareness in eight Asian countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

World Rabies Day: focusing attention on a neglected disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

An important date in rabies history.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970340-1

7 January 2021

10.1016/S1473-3099(11)70340-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22541629%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference